Cantor Fitzgerald Sticks to Their Buy Rating for Karyopharm Therapeutics

By Austin Angelo

Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI) today and set a price target of $18. The company’s shares opened today at $13.08.

Goldstein commented:

“KPTI reported top-line STORM data, which demonstrated a 25.4% ORR (2 CRs and 19 PRs) and 4.4 months DoR in penta-refractory myeloma patients. That means the company will be able to file an NDA for accelerated approval in this population in the U.S. and Europe.”

According to, Goldstein is ranked 0 out of 5 stars with an average return of -2.9% and a 37.1% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, CytomX Therapeutics Inc, and Cascadian Therapeutics.

Currently, the analyst consensus on Karyopharm Therapeutics is Strong Buy and the average price target is $22, representing a 68.2% upside.

In a report issued on April 16, H.C. Wainwright also maintained a Buy rating on the stock with a $26 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $18 and a one-year low of $7.48. Currently, Karyopharm Therapeutics has an average volume of 486.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, which discovers, develops, and commercializes drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma.